CN115666588A - Janus激酶抑制剂和端粒酶抑制剂用于治疗骨髓增殖性肿瘤的用途 - Google Patents

Janus激酶抑制剂和端粒酶抑制剂用于治疗骨髓增殖性肿瘤的用途 Download PDF

Info

Publication number
CN115666588A
CN115666588A CN202080091888.8A CN202080091888A CN115666588A CN 115666588 A CN115666588 A CN 115666588A CN 202080091888 A CN202080091888 A CN 202080091888A CN 115666588 A CN115666588 A CN 115666588A
Authority
CN
China
Prior art keywords
administered
days
subject
inhibitor
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080091888.8A
Other languages
English (en)
Chinese (zh)
Inventor
F·黄
X·王
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Icahn School of Medicine at Mount Sinai
Original Assignee
Geron Corp
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp, Icahn School of Medicine at Mount Sinai filed Critical Geron Corp
Publication of CN115666588A publication Critical patent/CN115666588A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080091888.8A 2019-11-04 2020-11-03 Janus激酶抑制剂和端粒酶抑制剂用于治疗骨髓增殖性肿瘤的用途 Pending CN115666588A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930251P 2019-11-04 2019-11-04
US62/930,251 2019-11-04
PCT/US2020/058718 WO2021091904A1 (en) 2019-11-04 2020-11-03 Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
CN115666588A true CN115666588A (zh) 2023-01-31

Family

ID=75848061

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080091888.8A Pending CN115666588A (zh) 2019-11-04 2020-11-03 Janus激酶抑制剂和端粒酶抑制剂用于治疗骨髓增殖性肿瘤的用途

Country Status (11)

Country Link
US (2) US12391946B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054594A4 (cg-RX-API-DMAC7.html)
JP (2) JP7767279B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220130669A (cg-RX-API-DMAC7.html)
CN (1) CN115666588A (cg-RX-API-DMAC7.html)
AU (1) AU2020380245A1 (cg-RX-API-DMAC7.html)
CA (1) CA3156376A1 (cg-RX-API-DMAC7.html)
IL (1) IL292596A (cg-RX-API-DMAC7.html)
MX (1) MX2022005354A (cg-RX-API-DMAC7.html)
TW (1) TW202133854A (cg-RX-API-DMAC7.html)
WO (1) WO2021091904A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法
EP4463151A4 (en) 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104168884A (zh) * 2011-11-01 2014-11-26 细胞基因公司 使用胞苷类似物的口服制剂治疗癌症的方法
CN104936602A (zh) * 2012-12-07 2015-09-23 美国杰龙生物医药公司 端粒酶抑制剂用于治疗骨髓增生性病症和骨髓增生性肿瘤的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102242077B1 (ko) * 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
US20150342982A1 (en) * 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104168884A (zh) * 2011-11-01 2014-11-26 细胞基因公司 使用胞苷类似物的口服制剂治疗癌症的方法
CN104936602A (zh) * 2012-12-07 2015-09-23 美国杰龙生物医药公司 端粒酶抑制剂用于治疗骨髓增生性病症和骨髓增生性肿瘤的用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLAIRE N HARRISON ET AL.: "Current treatment algorithm for the management of patients with myelofibrosis, JAK inhibitors, and beyond", 《HEMATOLOGY AM SOC HEMATOL EDUC PROGRAM》, no. 1, pages 1 *
XIAOLI WANG ET AL.: "Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells", 《BLOOD ADVANCES》, vol. 2, no. 18, pages 2379 *
肖超等: "慢性骨髓增殖性肿瘤临床研究进展", 《诊断学理论与实践》, vol. 13, no. 6, pages 630 *

Also Published As

Publication number Publication date
JP2025061603A (ja) 2025-04-10
US12391946B2 (en) 2025-08-19
TW202133854A (zh) 2021-09-16
EP4054594A4 (en) 2023-12-13
JP2023500326A (ja) 2023-01-05
JP7767279B2 (ja) 2025-11-11
IL292596A (en) 2022-07-01
MX2022005354A (es) 2022-10-21
EP4054594A1 (en) 2022-09-14
AU2020380245A1 (en) 2022-05-19
CA3156376A1 (en) 2021-05-14
WO2021091904A1 (en) 2021-05-14
US20210269807A1 (en) 2021-09-02
US20260078379A1 (en) 2026-03-19
KR20220130669A (ko) 2022-09-27

Similar Documents

Publication Publication Date Title
JP7288098B2 (ja) 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
US20220168333A1 (en) Combination Treatment for Hematological Cancers
US20260078379A1 (en) Use of a Janus Kinase Inhibitor and a Telomerase Inhibitor for the Treatment of Myeloproliferative Neoplasms
WO2018052120A1 (en) A hck inhibitor and a bcl-2 inhibitor for treating acute myeloid leukemia
IL324714A (en) Imetelstat for use in treating myelodysplastic syndrome
US20150342982A1 (en) Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
HK40087531A (en) Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms
HK40018627B (en) The telomerase inhibitor imetelstat for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
HK40018627A (en) The telomerase inhibitor imetelstat for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
CN116940365A (zh) 慢性髓性白血病干细胞抑制剂
HK40009285B (en) Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome
HK40009285A (en) Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome
HK40002948B (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
OA17327A (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms.
HK1212226B (en) Use of the telomerase inhibitor imetelstat for the treatment of myelofibrosis
HK40036832A (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40087531

Country of ref document: HK